Vanderbilt researchers have identified a new vulnerability in lung cancer — the transporter protein xCT — that may a therapeutic target for the disease.

Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.

Although cystic fibrosis (CF) has long been known as a pediatric disease, physicians and scientists at Vanderbilt University Medical Center are providing specialized care for an ever-growing population of adults with CF, as well as conducting targeted research expected to improve treatment for these patients.

Two early-career physician-scientists at Vanderbilt University Medical Center are among 18 recipients of 2018 Clinical Scientist Development Awards announced July 31 by the Doris Duke Charitable Foundation.

A receptor previously implicated in asthma may also play roles in other allergic diseases and in leukemia, Vanderbilt researchers have discovered.

Richard Lane, MD, assistant professor of Clinical Medicine and a senior member of Vanderbilt’s Internal Medicine group at Williamson County Medical Center, was recently elected a Master of the American College of Physicians.

A protein involved in binding cells together helps maintain the integrity of the intestinal mucosa and plays a protective role in ulcerative colitis.